T2 Biosystems, Inc. 8-K Report: Key Developments on February 20, 2025

Based on the provided section of the financial report, here are the key pieces of information extracted:

Entity Information:

Name: T2 Biosystems, Inc.
Incorporation: Delaware (DE)
CIK (Central Index Key): 0001492674
SEC File Number: 001-36571
EIN (Employer Identification Number): 20-4827488
Address: 101 Hartwell Avenue, Lexington, MA 02421
Phone Number: 781-761-4646

Filing Type:

Form Type: 8-K (used for current reports to disclose important events)

Reporting Period:

Date of Report: February 20, 2025
Period Covered: The report covers activities on the same date, February 20, 2025.

Stock Information:

Class of Stock: Common stock
Par Value: $0.001 per share

Filing Status:

The report indicates that certain standard disclosures (like financial data and material events) may not be included (as suggested by the "NONE false" entries).

Insights:

T2 Biosystems, Inc. is maintaining transparency by filing an 8-K, which is crucial for investors and analysts to understand any significant developments that may affect the company's standing.
The par value of the common stock is notably low, which can be common for startups or companies in specific industries looking to attract investment without a high initial share price.
The lack of additional data or disclosures may indicate that the filing pertains to a routine update, or it could be a placeholder for more detailed information to be provided later.

This summary provides a snapshot of T2 Biosystems, Inc. and highlights the importance of their ongoing disclosures to stakeholders in the context of SEC regulations.